Cellseed Inc. · TSE:7776
Cellseed — H1 2020 Earnings Presentation
25 slides from Cellseed's earnings presentation, Aug 21, 2020
Slide 1: Fiscal 2020 First-Half Earnings Results Presentation
CellSeed Inc. Fiscal 2020 First-Half Earnings Results Presentation JASDAQ Growth Stock Code:7776
Slide 2: Contents
Contents Company Profile Half-year financial summary FY 12/2020 Earnings forecast About our COVID-19 response Copyright © 2020 CellSeed Inc. All Rights Reserved. 1
Slide 3: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Established May, 2001 Core competence Cell Sheet Engineering based on Temperature Responsive Polymers Listed JASDAQ（7776) in 2010 Business Regenerative Medical Regenerative Medicine Products Business Supporting Business • Commercialization of Cell Sheet Therapies
Slide 4: Cell Sheet Engineering
“Cell Sheet Engineering” Platform Technology of Regenerative Medicine 37℃ Hydrophobic ⇔ 20℃ Hydrophilic Copyright © 2020 CellSeed Inc. All Rights Reserved. 3
Slide 5: Our Business Model
Our Business Model Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Medical Hospitals Seeds Products Patients Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partn
Slide 6: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering Copyright © 2020 CellSeed Inc. All Rights Reserved. 5
Slide 7: Expansion of Cell Sheet Engineering
Expansion of Cell Sheet Engineering 120 CSTEC 総出願件数 Patents 100 Papers ⽂献数 80 60 40 20 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Establishment of Overseas sales for CellSeed Inc Upcell🄬 launched…
Slide 8: Contents
Contents Company Profile Half-year financial summary FY 12/2020 Earnings forecast About our COVID-19 response Copyright © 2020 CellSeed Inc. All Rights Reserved. 7
Slide 9: Half-year financial summary FY 12/2020
Half-year financial summary FY 12/2020 First Half of the FY2019 First Half of the FY2020 Consolidated Consolidated （January 2020 - June 2020） （January 2019 - June 2019） Change from Amount Change Amount Previous Period （Millions of Yen） （Millions of Yen） （Millions of Yen） （%） Net sales 58 -104 -64.1
Slide 10: Epithelial Cell Sheet for Esophageal Regeneration
Epithelial Cell Sheet for Esophageal Regeneration (CLS2702C/D) A medical treatment developed by Tokyo Women’s Medical University as a regenerative treatment for esophageal cancer (to heal esophageal wound and prevent stricture) Cell sheet is on a temperature-responsive cell culture ware and then
Slide 11: Clinical Research and Clinical Trials of Esophageal Cell Sheet
Clinical Research and Clinical Trials of Esophageal Cell Sheet Tokyo Women’s Medical University Clinical Research at Universities 2008－2014＜Japan＞ Tokyo Womenʼs Medical Univ. 10case Tokyo Womenʼs Medical Univ. Basic 10case Development and Nagasaki Univ. Agreement ＜Europe＞ Karolinska University Hos
Slide 12: Chondrocyte Sheet
Chondrocyte Sheet Disease characteristics • Causes︓ageing・obesity traumatic • No treatment to regenerate lost cartilage is available In Japan, estimated number of potential patients about 30 million persons of which, about 10 million shows symptoms. Go Omori, Yoshio Koga and others From epidemio
Slide 13: Autologous chondrocyte sheets
Autologous chondrocyte sheets Started medial treatment in Tokai University as Advanced Medicine B Collect Autologous Manufacture Cell Transplant to Patient Cartilage Cells Sheet chondrocyte sheets Indications︓Knee Osteoarthritis Copyright © 2020 CellSeed Inc. All Rights Reserved. 12
Slide 14: Overview of Chondrocyte Sheet Project
Overview of Chondrocyte Sheet Project Started medial treatment in Tokai University as Advanced Medicine B Basic Development Agreement Developed by Prof. Masato Sato, Department of Orthopaedic Surgery, Taiwan Surgical Science, Tokai University School of Medicine ＜ Autologous Cells ＞ • Licensing out A
Slide 15: Allogeneic chondrocyte sheets
Allogeneic chondrocyte sheets Preparation of Cell Stock Master Working Cell Cell Bank Bank Cell Suspension Culture Evaluation test Quality/Safety In liq.Nitrogen In liq.Nitrogen Transport- ation Polydactyly donors Collection of tissue Manufacture Packaging Lot release test Thawing Culture CellSheet
Slide 16: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup UpCell® RepCell TM HydroCell ™ Cell Sheet Recovery Cell Recovery Ultra-Low Adhesion Cell （Temperature Sensitive） （Temperature Sensitive） Cultureware Temperature-responsive Temperature-responsive Low cell binding cell cultureware for "Cell
Slide 17: Sales of equipment and materials were healthy in domestic and abroad
Sales of equipment and materials were healthy in domestic and abroad. MiCAN Technologies Inc., which develops and sells cells for researching infectious diseases caused by the novel coronavirus, etc., has adopted HydroCell™, a cell cultureware of our company. Thanks to the enhanced cooperation w
Slide 18: Supplying cell cultureware equipment to a company developing cells for research on Novel coronavirus
Supplying cell cultureware equipment to a company developing cells for research on Novel coronavirus MiCAN Technologies Inc., our client, develops cells for researching various infectious diseases, including the novel coronavirus, and immune disorders, and has adopted HydroCell™, a cell cultureware
Slide 19: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business 1. Regenerative Cell Sheet Product Manufacture Method 2. Facility Management, 3. Cell Culturing Technician Development, Consigned Application Submission Support Training Manufacture Consigned manufacture Support for certification Cell sheet culturing t
Slide 20: POSTPONE: The 2nd Cell Sheet Engineering Innovation Forum
POSTPONE : The 2nd Cell Sheet Engineering Innovation Forum To prevent coronavirus infection, we adjourned The 2nd Cell Sheet Engineering Innovation Forum scheduled to be held in October 15 2020. We will contact you as soon as that forum date has been decided. Copyright © 2020 CellSeed Inc. All Right
Slide 21: Contents
Contents Company Profile Half-year financial summary FY 12/2020 Earnings forecast About our COVID-19 response Copyright © 2020 CellSeed Inc. All Rights Reserved. 20
Slide 22: Revisions to Full-Year Consolidated financial estimation for FY 12/2020
Revisions to Full-Year Consolidated financial estimation for FY 12/2020 Due to the pandemic of the novel coronavirus, the comprehensive development support for the joint venture established in Taiwan in Jan. 2020 was delayed, and our activities for forming business alliances and licensing in Asian c
Slide 23: Contents
Contents Company Profile Half-year financial summary FY 12/2020 Earnings forecast About our COVID-19 response Copyright © 2020 CellSeed Inc. All Rights Reserved. 22
Slide 24: Our response to Novel coronaviruses
Our response to Novel coronaviruses Since Feb. 27, 2020, our company has promoted employees to work from home, and as disclosed on Aug. 3, 2020, we will continue telework until Sep. 30, 2020. From now on, we will promote diverse workstyles according to the environment of each employee, including the
Slide 25: This presentation is made by CellSeed Inc. solely for the disclosure of the financial
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. Copyright © 2020 CellSeed Inc. All Rights Reserved.